Sichuan Hexie Shuangma Completes Acquisition of Biopharmaceutical Firm Shenzhen Jianyuan in Recent Years

Deep News02-03 21:31

Sichuan Hexie Shuangma Co.,Ltd. announced on February 3rd via an interactive platform response to investor inquiries that the company has successfully concluded its acquisition of the biopharmaceutical enterprise Shenzhen Jianyuan in recent years. This strategic move significantly expands the company's future development segments and substantially enhances its operational vitality.

Moving forward, the company will focus on consolidating its investment sector while simultaneously driving the in-depth development of its biopharmaceutical business. It aims to continuously improve operational efficiency and strive to create greater value and returns for shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175255262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175255262","market":"nz","top_or_hot":-1,"title":"Sichuan Hexie Shuangma Completes Acquisition of Biopharmaceutical Firm Shenzhen Jianyuan in Recent Years","media":"Deep News","content":"<p>Sichuan Hexie Shuangma Co.,Ltd. announced on February 3rd via an interactive platform response to investor inquiries that the company has successfully concluded its acquisition of the biopharmaceutical enterprise Shenzhen Jianyuan in recent years. This strategic move significantly expands the company's future development segments and substantially enhances its operational vitality.</p>\n<p>Moving forward, the company will focus on consolidating its investment sector while simultaneously driving the in-depth development of its biopharmaceutical business. It aims to continuously improve operational efficiency and strive to create greater value and returns for shareholders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Hexie Shuangma Completes Acquisition of Biopharmaceutical Firm Shenzhen Jianyuan in Recent Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Hexie Shuangma Completes Acquisition of Biopharmaceutical Firm Shenzhen Jianyuan in Recent Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-02-03 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Hexie Shuangma Co.,Ltd. announced on February 3rd via an interactive platform response to investor inquiries that the company has successfully concluded its acquisition of the biopharmaceutical enterprise Shenzhen Jianyuan in recent years. This strategic move significantly expands the company's future development segments and substantially enhances its operational vitality.</p>\n<p>Moving forward, the company will focus on consolidating its investment sector while simultaneously driving the in-depth development of its biopharmaceutical business. It aims to continuously improve operational efficiency and strive to create greater value and returns for shareholders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0235","symbol_name":"非金矿物","start_time":0,"source_url":"","article_id":"1175255262","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175255262","pubTimestamp":1770125483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Sichuan Hexie Shuangma Co.,Ltd. announced on February 3rd via an interactive platform response to investor inquiries that the company has successfully concluded its acquisition of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","399441":"生物医药","BK0235":"非金矿物","000935":"四川双马","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","BK0004":"股权转让","BK0021":"外资并购(国际板)","BK0028":"国家队"},"translate_title":"四川和谐双马近年完成对生物制药公司深圳建元的收购","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"000935":1,"LABU":1},"content_text":"Sichuan Hexie Shuangma Co.,Ltd. announced on February 3rd via an interactive platform response to investor inquiries that the company has successfully concluded its acquisition of the biopharmaceutical enterprise Shenzhen Jianyuan in recent years. This strategic move significantly expands the company's future development segments and substantially enhances its operational vitality.\nMoving forward, the company will focus on consolidating its investment sector while simultaneously driving the in-depth development of its biopharmaceutical business. It aims to continuously improve operational efficiency and strive to create greater value and returns for shareholders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175255262","isCrawlerRequest":true}